Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H20FN3O4.C3H6O3 |
Molecular Weight | 451.4454 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 2 |
E/Z Centers | 0 |
Charge | 0 |
Stereo Comments | C3 H6 O3 |
SHOW SMILES / InChI
SMILES
CC(O)C(O)=O.C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4
InChI
InChIKey=ONDRRTIAGBDDKP-PPHPATTJSA-N
InChI=1S/C18H20FN3O4.C3H6O3/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;1-2(4)3(5)6/h7-8,10H,3-6,9H2,1-2H3,(H,24,25);2,4H,1H3,(H,5,6)/t10-;/m0./s1
Molecular Formula | C18H20FN3O4 |
Molecular Weight | 361.3675 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C3H6O3 |
Molecular Weight | 90.0779 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Levofloxacin is used for oral and intravenous administration. Levofloxacin is sold under brand name levaquin and is used to treat infections in adults (≥18 years of age) caused by designated, susceptible bacteria such as, pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. In addition this drug is used to treat plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Levofloxacin, like other fluoroquinolones, inhibits the bacterial DNA gyrase, halting DNA replication. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing. In addition, levofloxacin inhibits a bacterial type II topoisomerase.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14506016
Curator's Comment: levofloxacin penetrates the cerebrospinal fluid (CSF) during meningeal inflammation both in animals and in humans
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363033 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26525786 |
|||
Target ID: CHEMBL2311225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26459538 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.9 mg/L |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.8 mg/L |
500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
11.8 mg/L |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.85 mg/L |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
2.04 mg/L |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.3 mg/L |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
49.6 mg × h/L |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
59 mg × h/L |
500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
118 mg × h/L |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
111 mg × h/L |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
19.88 mg × h/L |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
55.3 mg × h/L |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.6 h |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.4 h |
500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.9 h |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.9 h |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
5.97 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.6 h |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Sources: Page: 19Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Sources: Page: 19Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.2%) Sources: Page: 19Nausea (0.6%) Vomiting (0.5%) Dizziness (0.3%) Headache (0.3%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headache | 0.2% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Dizziness | 0.3% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Vomiting | 0.4% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Nausea | 0.6% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Gastrointestinal disorder | 1.4% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Headache | 0.2% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Dizziness | 0.3% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Vomiting | 0.4% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Nausea | 0.6% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Gastrointestinal disorder | 1.4% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Dizziness | 0.3% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Headache | 0.3% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Vomiting | 0.5% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Nausea | 0.6% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Gastrointestinal disorder | 1.2% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
inconclusive | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
weak | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: - |
yes [IC50 210 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/16928358/ Page: - |
yes [IC50 6800 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
yes |
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/16474415/ Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. | 1999 Dec |
|
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening. | 2000 Oct |
|
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. | 2000 Sep |
|
In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci. | 2001 |
|
[Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria]. | 2001 Apr |
|
Enantioseparation of ofloxacin in urine by capillary electrokinetic chromatography using charged cyclodextrins as chiral selectors and assessment of enantioconversion. | 2001 Apr |
|
[Injectable quinolones]. | 2001 Apr |
|
Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. | 2001 Apr |
|
Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. | 2001 Apr |
|
Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. | 2001 Feb |
|
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study. | 2001 Feb |
|
[In vitro antimycobacterial activities of a new quinolone, balofloxacin]. | 2001 Jan |
|
In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae. | 2001 Jan |
|
Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. | 2001 Jan |
|
Use of a recombinant strain of Mycobacterium avium expressing beta-galactosidase to evaluate the activities of antimycobacterial agents inside macrophages. | 2001 Jan |
|
New directions in antiinfective therapy for community-acquired pneumonia in the emergency department. | 2001 Jul |
|
The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice. | 2001 Jul |
|
Activity of levofloxacin and ciprofloxacin against urinary pathogens. | 2001 Jul |
|
Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates from Crete, Greece. | 2001 Jun |
|
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. | 2001 Jun |
|
Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages. | 2001 Mar |
|
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. | 2001 Mar |
|
Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. | 2001 Mar |
|
In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany. | 2001 Mar-Apr |
|
Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. | 2001 May |
|
Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery. | 2001 May |
|
Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones. | 2001 May |
|
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification. | 2001 Spring |
Sample Use Guides
The usual dose of LEVAQUIN tablets or oral solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours. The usual dose of LEVAQUIN Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours.
Nosocomial Pneumonia: 750 mg during 7–14 days
Community Acquired Pneumonia: 500 mg during 7–14 days
Community Acquired Pneumonia§ 750 mg during 5 days
Complicated Skin and Skin Structure Infections (SSSI) 750 mg during 7–14 days
Uncomplicated SSSI 500 mg during 7–10 days
Chronic Bacterial Prostatitis 500 mg during 28 days
Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 750 mg during 5 days
Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 250 mg during 10 days
Uncomplicated Urinary Tract Infection 250 mg 3 during days
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg during 7 days
Acute Bacterial Sinusitis (ABS) 750 mg days or 500 mg during 10–14 days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8077990
Levofloxacin was compared to ofloxacin and ciprofloxacin against > 6000 recent clinical isolates of Gram-positive and Gram-negative bacteria from six different countries. This international multicenter study demonstrated a high level of antibacterial activity of levofloxacin against all the members of Enterobacteriaceae [minimum inhibitory concentration (MIC)50s, < or = 0.03 to 0.12 mg/L] except Providencia rettgeri (MIC50, 2 mg/L), and Providencia stuartii (MIC50, 1 mg/L). Levofloxacin was also active against non-enteric Gram-negative bacilli, including Acinetobacter species (MIC50s, < or = 0.03 to 1 mg/L), Pseudomonas species (MIC50s, 0.5 to 1 mg/L) and Xanthomonas maltophilia (MIC50, 0.5 mg/L). Overall, levofloxacin inhibited 50% and 90% of all the tested strains at the concentrations of 0.12 and 4 mg/L, respectively. The activity of levofloxacin was generally two-fold greater than ofloxacin and equal to or slightly less potent than ciprofloxacin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 23:13:07 UTC 2022
by
admin
on
Sat Dec 17 23:13:07 UTC 2022
|
Record UNII |
NHR291QA18
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
97853-07-1
Created by
admin on Sat Dec 17 23:13:07 UTC 2022 , Edited by admin on Sat Dec 17 23:13:07 UTC 2022
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
25119532
Created by
admin on Sat Dec 17 23:13:07 UTC 2022 , Edited by admin on Sat Dec 17 23:13:07 UTC 2022
|
PRIMARY | |||
|
SUB121291
Created by
admin on Sat Dec 17 23:13:07 UTC 2022 , Edited by admin on Sat Dec 17 23:13:07 UTC 2022
|
PRIMARY | |||
|
DTXSID00648769
Created by
admin on Sat Dec 17 23:13:07 UTC 2022 , Edited by admin on Sat Dec 17 23:13:07 UTC 2022
|
PRIMARY | |||
|
294662-18-3
Created by
admin on Sat Dec 17 23:13:07 UTC 2022 , Edited by admin on Sat Dec 17 23:13:07 UTC 2022
|
PRIMARY | |||
|
NHR291QA18
Created by
admin on Sat Dec 17 23:13:07 UTC 2022 , Edited by admin on Sat Dec 17 23:13:07 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |